A Novel Tri-Allelic Insertion/Deletion Polymorphism in the Promoter of p21Waf1Cip1 and the Association with Gastric Cancer

被引:2
作者
Chen, Zhiqiang [1 ,2 ]
Dong, Ying [1 ]
Wang, Ningju [3 ]
Liang, Hanmei [1 ]
Du, Yong [4 ]
Ye, Xiaofeng [3 ]
Jia, Wei [4 ]
He, Zhongyi [1 ]
Jiang, Yideng [1 ]
Yang, Yinxue [3 ,4 ]
Yang, Wenjun [1 ,3 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Oncol, Canc Hosp,Key Lab Reprod & Hered, Yinchuan 750004, Peoples R China
[2] Ningxia Med Univ, Dept Radiol, Gen Hosp, Yinchuan 750004, Peoples R China
[3] Ningxia Med Univ, Dept Oncol, Canc Hosp & Inst, Gen Hosp, Yinchuan 750004, Peoples R China
[4] Ningxia Med Univ, Gen Hosp, Surg Lab, Yinchuan 750004, Peoples R China
基金
中国国家自然科学基金;
关键词
SMALL INSERTIONS; P53; P21; P21(WAF1/CIP1); DELETIONS;
D O I
10.1089/gtmb.2013.0375
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aims: p21(Waf1/Cip1) is a cyclin-dependent kinase inhibitor that is pivotal in arresting cellular growth in terminal cell differentiation and apoptosis. Thus, the existence of natural variants of p21(Waf1/Cip1) could be linked to specific cancer. The purpose of this report was to identify a novel tri-allelic insertion/deletion (INDEL) polymorphism (rs4135235) involving a poly-T sequence in the promoter region of p21(Waf1/Cip1) gene and to explore its role in gastric cancer (GC). Method: A total of unrelated 676 subjects (376 GC patients; 300 cancer-free controls) were enrolled in the study, and genomic DNA was obtained from each subject for genotyping. PCR-directed sequencing technique was used to detect the genotypes of the polymorphism. TA cloning was used to confirm the existence of three alleles. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression analysis. Results: Six genotypes (9T/9T, 10T/10T, 11T/11T, 9T/10T, 10T/11T, and 9T/11T) and three alleles (9Ts, 10Ts, and 11Ts) were identified among all study subjects. GC cases were different from the control group with over-representation of 9T/11T heterozygotes (19.7% vs. 12.3%) and under-representation of 10T/10T homozygotes (18.4% vs. 20.7%). Compared with those carrying 10T/10T, individuals with 9T/11T increased the susceptibility for GC (OR=1.797, 95%CI=1.065-3.031). Conclusion: Our findings confirmed the existence of a tri-allelic polymorphism in the promoter of p21(Waf1/Cip1). It has also shown the heterozygous genotype 9T/11T to be a potential risk factor for GC in the Chinese population.
引用
收藏
页码:112 / 116
页数:5
相关论文
共 17 条
[1]   p21 in cancer: intricate networks and multiple activities [J].
Abbas, Tarek ;
Dutta, Anindya .
NATURE REVIEWS CANCER, 2009, 9 (06) :400-414
[2]   Recent patterns in gastric cancer: A global overview [J].
Bertuccio, Paola ;
Chatenoud, Liliane ;
Levi, Fabio ;
Praud, Delphine ;
Ferlay, Jacques ;
Negri, Eva ;
Malvezzi, Matteo ;
La Vecchia, Carlo .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (03) :666-673
[3]   Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].
Bunz, F ;
Dutriaux, A ;
Lengauer, C ;
Waldman, T ;
Zhou, S ;
Brown, JP ;
Sedivy, JM ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 1998, 282 (5393) :1497-1501
[4]   p21WAF1/Cip1:: more than a break to the cell cycle? [J].
Dotto, GP .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2000, 1471 (01) :M43-M56
[5]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[6]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[7]   Lost in transcription: p21 repression, mechanisms, and consequences [J].
Gartel, AL ;
Radhakrishnan, SK .
CANCER RESEARCH, 2005, 65 (10) :3980-3985
[8]   The role of mutant p53 in human cancer [J].
Goh, Amanda M. ;
Coffill, Cynthia R. ;
Lane, David P. .
JOURNAL OF PATHOLOGY, 2011, 223 (02) :116-126
[9]   Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment [J].
Hrstka, Roman ;
Coates, Philip J. ;
Vojtesek, Borivoj .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (03) :440-453
[10]  
Jemal A, 2009, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/caac.20107